Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Amunix Announces Licensing Agreement For Its Proprietary XTEN Technology



  Amunix Announces Licensing Agreement For Its Proprietary XTEN Technology

PepTalk: The Protein Science Week

Business Wire

MOUNTAIN VIEW, Calif. -- January 21, 2013

Amunix, Inc., today announced that it has entered into a worldwide research
collaboration and licensing agreement with Janssen Biotech, Inc. and its
affiliates (“Janssen”). Amunix will combine its XTEN half-life extension
technology with protein and/or peptide therapeutics selected by Janssen.

Under the terms of the agreement, Amunix will assist Janssen in the
engineering of up to three XTEN fusion proteins. Janssen will be responsible
for all preclinical and clinical development as well as for manufacturing and
commercialization of the resulting products. Amunix will receive an initial
upfront payment in addition to R&D funding and will be eligible for future
milestone and royalty payments. Additional financial terms will not be
disclosed.

“We are pleased to be collaborating with Janssen,” said Volker Schellenberger,
Ph.D., President of Amunix. “Amunix’s XTEN polymer can be combined with a wide
range of proteins and peptides. Collaborations such as this are a central
element of our strategy to facilitate the use of XTEN in a wide range of
therapeutic applications.”

About Amunix

Amunix, Inc., based in Mountain View, CA, is a privately held biotechnology
company focused on the discovery and development of novel therapeutics with
improved in vivo half-lives. Amunix’s half-life extension technology is based
on XTEN, a unique, biodegradable polymer. XTEN is a hydrophilic, unstructured
polypeptide that imparts a number of favorable properties upon the molecules
to which it is attached. XTEN can be recombinantly fused to protein-based
pharmaceuticals or chemically conjugated to peptides, proteins, and other
molecules. Besides the advantages of a lower dosing frequency, XTENylation
also stabilizes plasma drug concentrations, which can result in increased
potency as well as reduced side effects.

Contact:

MBI Consulting for Amunix
Anja Krammer, 650-889-5022
anja.krammer@mbi-consulting.com
www.mbi-consulting.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement